Stereotaxis Inc. (STXS)
NYSE: STXSHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STXS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $95.03M
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- 52-week range
- 0.80 – 2.86
- Day range
- 0.9031 – 1.01
- Volume / Avg
- 1.25M / 715.12K
- Beta
- —
- Shares outstanding
- 100.86M
52-week range
STXS stock today
On Nov 20, STXS ended the session at $0.9422, shedding $0.0678 (6.71%), versus the S&P 500's 3.70% decline. At this level, STXS sits near the bottom of its 52-week range of $0.80 to $2.86: 67.1% below the high, set on Jan 15, 2026 and 17.8% above the low. STXS is down 59.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 59.4%.
Stereotaxis has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Stereotaxis
Company profileStereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
- Headquarters
- Saint Louis, MO
- Employees
- 131
- Website
- stereotaxis.com
Financial highlights
Full financialsIn fiscal 2025, Stereotaxis generated $32.4 million in revenue, up 20.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Stereotaxis reported a net loss of $21.6 million, compared with a loss of $24.0 million a year earlier. Gross margin was 52.7% (down from 54.2%) and operating margin -68.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $32.38M | $26.92M | $26.77M | $28.15M | $35.02M |
| Growth | +20.28% | +0.55% | -4.89% | -19.63% | +31.51% |
| Net income | $-21.64M | $-24.05M | $-20.71M | $-18.29M | $-10.72M |
| EPS (diluted) | $-0.25 | $-0.30 | $-0.27 | $-0.26 | $-0.16 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$3.00+218.40%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.03 vs —
STXS news
All STXS news- Stereotaxis (STXS) Q3 2026 Earnings Call TranscriptNasdaq
- Stereotaxis Reports 2026 Third Quarter Financial Results & Business UpdatesGlobeNewswire
- Stereotaxis Announces Convertible Note Financing of Up To $24 MillionGlobeNewswire
- First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCTGlobeNewswire
- Canon Medical, Stereotaxis Partner On Robotic Electrophysiology LabsNasdaqSTXS, LEN.B
- Canon Medical and Stereotaxis Collaborate to Advance Robotic ElectrophysiologyGlobeNewswire
- Stereotaxis Announces First Robotic Magnetic Navigation System in LatviaGlobeNewswire
- Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswire
Stereotaxis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HSDTSolana Company Class A | 1.49 | -10.24% | $93.70M | vs STXS |
| VANIVivani Medical Inc. | 1.14 | +4.59% | $102.83M | vs STXS |
| FOCLEDAP TMS S.A. ADR | 2.61 | -7.45% | $123.25M | vs STXS |
| NRXSNeuraxis Inc. | 4.22 | -6.22% | $59.90M | vs STXS |
| HYPRHyperfine Inc. Class A | 0.5465 | +4.27% | $57.96M | vs STXS |
| OMOutset Medical Inc. | 2.81 | -3.44% | $53.03M | vs STXS |
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs STXS |
| ECORelectroCore Inc. | 4.42 | -8.87% | $40.78M | vs STXS |
Indexes, lists and sector
Stereotaxis stock FAQ
What is Stereotaxis's stock price today?
STXS last traded at $0.9422 as of Nov 20, 4:00 PM EST, down 6.71% on the day. Prices are delayed at least 15 minutes.
Does Stereotaxis pay a dividend?
No. Stereotaxis does not currently pay a regular cash dividend.
Who is Stereotaxis's CEO?
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. is the chief executive officer of Stereotaxis Inc., which has about 131 employees.
Has STXS ever split its stock?
Yes. The most recent STXS stock split was a 1096-for-1000 split on Nov 4, 2013, one of 2 splits on record.
What is the STXS 52-week high?
The 52-week high for STXS is $2.86 and the 52-week low is $0.80. The stock is currently 67.1% below its high.